KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Free Cash Flow (2020 - 2025)

Aurinia Pharmaceuticals' Free Cash Flow history spans 6 years, with the latest figure at $45.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 51.69% year-over-year to $45.6 million; the TTM value through Dec 2025 reached $135.4 million, up 206.99%, while the annual FY2025 figure was $135.4 million, 206.99% up from the prior year.
  • Free Cash Flow reached $45.6 million in Q4 2025 per AUPH's latest filing, up from $44.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $45.6 million in Q4 2025 to a low of -$53.7 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$5.0 million, with a median of -$8.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 136.53% in 2021, then surged 623.31% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$26.9 million in 2021, then soared by 138.42% to $10.3 million in 2022, then soared by 35.84% to $14.0 million in 2023, then soared by 114.5% to $30.1 million in 2024, then skyrocketed by 51.69% to $45.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Free Cash Flow are $45.6 million (Q4 2025), $44.4 million (Q3 2025), and $44.1 million (Q2 2025).